MImAbs offers a number of ready-to-use syngeneic (for antibody alone or in combination with checkpoint inhibitors) and xenogeneic models, as well as customized models when contracted in an integrated offer.
Targeted cytotoxic compounds (e.g. ADCs):
Xenograft models
Principle. Cancer cells of human origin are grafted into immunodeficient mice.
Use. These models are used to address the efficacy of an antibody or ADC on mice bearing a target-positive xenografted tumour.
Material. Available models are listed here. Additional models can be generated on demand.
Patient-derived xenograft models
Principle.Cancer cells derived from patient samples are grafted into immunodeficient mice.
Use. These models are also used to address the efficacy of an antibody or ADC with the added value of testing the performance of the therapy directly on patient cells.
Material. Patient samples are available through collaborations with the CRCM and IPC.
Anti-human non-cross-reactive antibodies:
Genetically engineered mouse models
Development of a specific mouse model that expresses the human target protein is required. MImAbs offers on-demand genetic engineering in collaboration with CIPHE for the generation of knock-in, knock-out or humanized mouse models.
Antibodies that require immune effector cells to kill cancer cells:
Syngeneic models
Principle.Tumour cells derived from the same genetic background as the mouse strain used are grafted into immunocompetent animals.
Use. These models are used to study cancer therapies that modulate the immune system to increase or activate the native anti-tumour response.
Material.Available models are listed here . Additional models can be generated on demand.